摘要
目的探讨改良B-NHL-BFM95方案治疗儿童非霍奇金淋巴瘤的临床疗效和毒副反应。方法入组20例经病理确诊的14岁以下非霍奇金淋巴瘤患者,均接受改良B-NHL-BFM95方案治疗,未行放疗。结果近期疗效：18例（90.0%）CR,2例（10.0%）PD。治疗期间大部分患者出现Ⅲ、Ⅳ度骨髓抑制,经对症处理恢复正常,不影响下一步治疗。中位随访55个月,全组3 a无事件生存率80.0%,Ⅰ~Ⅱ期100.0%,Ⅲ~Ⅳ期60.0%;低危组100.0%,中危组85.7%,高危组50.0%。结论改良B-NHL-BFM-95方案治疗儿童非霍奇金淋巴瘤,特别是低、中危儿童非霍奇金淋巴瘤疗效显著,毒副反应可耐受。
Objective To evaluate the efficacy and toxicities of modified B-NHL-BFM95 regimen in the treatment of non-Hodgkin lymphoma in children. Methods Twenty patients with untreated non-Hodgkin lymphoma aged less than 14 were enrolled,and received modified B-NHL-BFM95 regimen. Results The short-term efficacy： 18 patients（ 90. 0%） achieved CR,2 patients（ 10. 0%） had PD. Grade Ⅲ and Ⅳ myelosuppression occurred in most patients,were recovered by active support care and did not affect the next course of chemotherapy. At a median followup of 55 months,the 3-year event-free survival rate was 80. 0% for all the patients,with 100. 0% for stage Ⅰ-Ⅱand 60. 0% for stage Ⅲ-Ⅳ patients; 100. 0% for the low risk group,85. 7% for the moderate risk group and 50.0% for the high risk group. Conclusion Modified B-NHL-BFM-95 regimen can improve the responses and survival of low-moderate risk non-Hodgkin lymphoma in children with tolerable toxicities.
出处
《肿瘤基础与临床》
2016年第5期380-383,共4页
journal of basic and clinical oncology
基金
国家临床重点专科建设项目
